Exelixis (EXEL) Interest & Investment Income (2017 - 2026)
Exelixis (EXEL) recorded quarterly Interest & Investment Income of $16.1 million in Q2 2026, down 7.45% quarter-over-quarter from $17.4 million in Q1 2026, and down 15.46% on a YoY basis from $19.1 million in Q2 2025.
Exelixis (EXEL) Interest & Investment Income (2017 - 2026) Analysis & Trends
Exelixis' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $16.1 million for Q2 2026.
- In Q2 2026, Interest & Investment Income fell 15.46% year-over-year to $16.1 million; the TTM figure through Apr 2026 stood at $66.3 million (down 13.2% YoY), while the FY2026 annual figure was $69.2 million, down 10.29% from the prior year.
- Interest & Investment Income was $16.1 million for Q2 2026 at Exelixis, down from $17.4 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $23.1 million in Q3 2023 to a low of $1.8 million in Q2 2022.
- Historically, Interest & Investment Income has averaged $16.6 million across 5 years, with a median of $17.4 million in 2026.
- Biggest YoY gain for Interest & Investment Income was 1078.9% in 2022; the steepest drop was 32.07% in 2022.
- A 5-year view of Interest & Investment Income shows it stood at $17.0 million in 2022, then increased by 25.9% to $21.4 million in 2023, then decreased by 12.53% to $18.7 million in 2024, then fell by 14.9% to $15.9 million in 2025, then gained by 1.29% to $16.1 million in 2026.
- The last three Interest & Investment Income figures came in at $16.1 million (Q2 2026), $17.4 million (Q1 2026), and $15.9 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | Exelixis | 13.61 Bn | 12.83 Bn | 590.86 Mn | 16.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 16.13 Mn |
| Jan 2, 2026 | 17.43 Mn |
| Oct 3, 2025 | 15.92 Mn |
| Jul 4, 2025 | 16.79 Mn |
| Apr 4, 2025 | 19.08 Mn |
| Jan 3, 2025 | 21.30 Mn |
| Sep 27, 2024 | 18.71 Mn |
| Jun 28, 2024 | 17.26 Mn |
| Mar 29, 2024 | 19.89 Mn |
| Dec 29, 2023 | 21.39 Mn |
| Sep 29, 2023 | 23.11 Mn |
| Jun 30, 2023 | 22.54 Mn |
| Mar 31, 2023 | 19.50 Mn |
| Dec 30, 2022 | 16.99 Mn |
| Sep 30, 2022 | 9.50 Mn |
| Jul 1, 2022 | 4.76 Mn |
| Apr 1, 2022 | 1.82 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Oct 1, 2021 | 1.66 Mn |
| Jul 2, 2021 | 1.89 Mn |